John Otrompke | Authors


Expanding the Reach of Immunotherapies for Kidney Cancer

November 08, 2016

David F. McDermott, MD, discusses methods of expanding on progress seen in the field of immunotherapy, both in the case of kidney cancer and other tumor types at the PER® European Congress on Immunotherapies in Cancer held in Barcelona.

Molecular Profiling on the Uptake for Increased Targeted Therapies in Bladder Cancer

November 03, 2016

The recommendation for molecular testing made in the second revision of the 2016 guidelines on bladder cancer from the National Comprehensive Cancer Network (NCCN) could make a considerable difference in increasing the amount of trials and targeted therapies in the long run for subtypes of patients with bladder cancer.

Insight into Drug Therapy and Stem Cell Transplant Options for Relapsed Myeloma Patients

August 26, 2016

A set of guidelines for treating patients with relapsed and refractory multiple myeloma published by the International Myeloma Working Group may not aid researchers in identifying ideal treatment paths for those with relapsed and refractory disease until more genomic data has been gathered.

Drug Interactions and Dosing Issues Complicate Newly Approved mCRPC Therapies

August 25, 2016

Approximately four years after the FDA approval of two powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis heightened clinical awareness of the potential for both under-treatment and over-treatment with abiraterone acetate, as well as potential drug-drug interactions with both abiraterone acetate and enzalutamide.

Regorafenib Use Beyond Progression Explored in Colorectal Cancer Case Study

June 28, 2016

Many patients with metastatic colorectal cancer (CRC) will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

Plasma Tests Can Complement Tissue Assays in Screening for Drug Resistance Mutation

June 10, 2016

Plasma and urine tests are often a reliable method for the detection of the T790M mutation in non-small cell lung cancer (NSCLC) patients with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs), according to an oral presentation given Monday at the 2016 ASCO Annual Meeting in Chicago.